Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001465 · ClinicalTrials.gov registry record
Study of the Disease Process of Lymphangioleiomyomatosis
A clinical trial of Lymphangioleiomyomatosis and Pneumothorax, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Recruiting
- Registry status
- 2,000
- Enrollment target
- 1
- Study location
NCT00001465 is a study of Lymphangioleiomyomatosis and Pneumothorax that is actively recruiting participants, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 2,000 participants, above the 630-participant average among 10 other Lymphangioleiomyomatosis trials with a reported enrollment target (217% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00001465, a study of Lymphangioleiomyomatosis and Pneumothorax, is actively recruiting participants, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- RECRUITING
- Registry status
- 2,000 participants
- Enrollment target
- 1
- Study location
Study Summary
Pulmonary lymphangioleiomyomatosis (LAM) is a destructive lung disease typically affecting women of childbearing age. Currently, there is no effective therapy for the disease and the prognosis is poor. This study is designed to determine the disease processes involved at the level of cells and molecules, in order to develop more effective therapy. Researchers intend to identify the proteins and genes that contribute to the process of lung destruction in affected individuals.
Conditions Studied
Interventions
- DEVICE Toshibia Aquilion One CT
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 1995-12-18 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001465
The ClinicalTrials.gov registry entry for NCT00001465 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 2,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 630-participant average among 10 other Lymphangioleiomyomatosis trials with a reported enrollment target (217% higher). The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Lymphangioleiomyomatosis appearing as the primary indexed condition, and to 1 intervention - of which Toshibia Aquilion One CT is the first listed.
NCT00001465 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00001465 about?
NCT00001465 is a clinical study titled "Study of the Disease Process of Lymphangioleiomyomatosis". Pulmonary lymphangioleiomyomatosis (LAM) is a destructive lung disease typically affecting women of childbearing age. Currently, there is no effective therapy for the disease and the prognosis is poor. This study is designed to determine the disease processes involved at the level of cells and mole...
What is the current status of trial NCT00001465?
This trial is currently recruiting. The enrollment target is 2,000 participants. The study started on 1995-12-18.
What conditions does trial NCT00001465 study?
This clinical trial studies the following conditions: Lymphangioleiomyomatosis, Pneumothorax, Tuberous Sclerosis, Lung Disease.
What interventions are being tested in trial NCT00001465?
The interventions under investigation include: Toshibia Aquilion One CT (DEVICE).
Who is sponsoring clinical trial NCT00001465?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00001465 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphangioleiomyomatosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis
RECRUITING · Phase 1
-
Safety and Durability of Sirolimus for Treatment of LAM
RECRUITING
-
TSC Biosample Repository and Natural History Database
RECRUITING
-
Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry)
RECRUITING
-
Evaluating the Long-term Safety and Tolerability of Imatinib in Patients With Lymphangioleiomyomatosis (LAM)
RECRUITING · Phase 1
-
Feasibility of [11C]Acetate-PET in LAM and TSC
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.